Cardiff Oncology, Inc. (CRDF) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $0.89. The rating moved from Neutral to Oversold on August 15, 2026.

• Public ratingOversold (as of August 19, 2026)
• Last close$0.89
• Last changeMoved from Neutral to Oversold on August 15, 2026
• SectorHealthcare
• IndustryBiotechnology

See all oversold Healthcare stocks →

AI analysis

Cardiff Oncology is an early-stage oncology company with upside tied to successful clinical progress and potential partnership interest, but the shares are constrained by limited liquidity, likely near-term financing needs, and high clinical/regulatory risk. Sector dynamics (diagnostics and biologics demand) and a modestly constructive market tone provide some support for speculative interest. Short-term price movements will be driven by any clinical updates, financing announcements, or strategic transactions; absent positive catalysts, downside remains a meaningful risk due to dilution and competitive pressures.

Key factors

• Early-stage oncology focus with high scientific upside if clinical data readouts are positive
• Small market capitalization and low liquidity that can amplify moves on news or financing events
• Sector tailwinds for oncology diagnostics and targeted therapies could increase strategic interest or partnership opportunities
• Limited publicly available recent financial filings and potential short cash runway increases likelihood of dilutive financing
• Management execution and clarity on clinical development milestones are primary near-term value drivers
• Macro environment is cautiously optimistic, supporting risk-on flows into growth/biotech but not eliminating sector-specific risk

Risks

• Clinical trial failures or delayed readouts that materially reduce valuation
• Near-term cash runway concerns requiring dilutive equity raises or unfavorable financing terms
• Regulatory setbacks or additional data requirements from FDA/other agencies
• Intense competition in oncology and diagnostics from larger, better-funded players and CRO/CDMO providers
• Low trading liquidity leading to volatile price action on small-volume news or block trades
• Limited visibility into revenue generation and commercialization pathway for lead assets

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.